Scarica l'app Stockscreener
3.15
1.61%
0.05
Pre-mercato:
3.23
0.08
+2.54%
Aclarion Inc Borsa (ACON) Ultime notizie
Insider Move: Aclarion Director Makes Bold New Share Purchase - TipRanks
Aclarion director Scott Breidbart acquires $18,011 in stock - Investing.com
Aclarion director Scott Breidbart acquires $18,011 in stock By Investing.com - Investing.com India
Director at Aclarion (ACON) buys 5,664 Common Stock shares in public trade - Stock Titan
Aclarion director David Neal buys $7,750 in company stock By Investing.com - Investing.com Nigeria
Aclarion director David Neal buys $7,750 in company stock - Investing.com
Aclarion (NASDAQ: ACON) director purchases 2,500 shares in open market trade - Stock Titan
TradingKey - TradingKey
Top Executive Makes Bold Insider Move at Aclarion, Inc. - TipRanks
Aclarion (ACON) CEO makes open-market share purchase - Stock Titan
What Aclarion (ACON) is doing that smart money tracks (Momentum Building) 2026-05-08Oversold Bounce - newser.com
Aclarion (ACON) director adds 1,562 shares in open-market purchase - Stock Titan
ACONW (Aclarion WT) quarterly update shows limited financial disclosure as investors await complete earnings details.High Interest Stocks - newser.com
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial By Investing.com - Investing.com South Africa
Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial - Investing.com
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment - The Manila Times
Beverly Hills spine practice joins 300-patient back pain trial - Stock Titan
Aclarion Announces Addition of First Private Practice Site in Los Angeles Into CLARITY Trial to Further Accelerate Enrollment - 富途牛牛
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - Orthopedics This Week
Aclarion Grants Inducement Stock Option to New Western U.S. Commercial Director Amid Growing Demand for Nociscan - citybuzz -
Aclarion Grants Commercial Director Stock Options for 75,000 Shares - geneonline.com
New Western U.S. director gets 17,000-share Aclarion option - Stock Titan
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. - marketscreener.com
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com India
Why Aclarion WT (ACONW) might surprise investors this quarter (Smart Money Exits) 2026-05-05Retail Trader Ideas - newser.com
Aclarion establishes second trial agreement with Weill Cornell - Investing.com
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
What Aclarion (ACON) is doing that smarter investors notice (Slips) 2026-05-05Elite Trading Signals - newser.com
ACONW (Aclarion WT) full quarterly earnings data not yet released, investors await key performance and guidance details.Performance Review - newser.com
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Is Aclarion (ACON) stock suitable for your portfolio? (-3.26%) 2026-04-29High Attention Stocks - newser.com
Recent Insider BuyingStock ScreenerSnapshot - Finviz
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
2.05%
2.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):